Compare iShares MSCI Indonesia ETF (EIDO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs TransMedics Group Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.47, while TransMedics Group Inc trades at $87.02 (market cap $3.10B). Which is the better fit depends on your goals.
| EIDO | TMDX | |
|---|---|---|
52-Week High | $19.22 | $150.42 |
52-Week Low | $10.80 | $61.99 |
Market Cap | — | $3.10B |
Sector | — | Technology |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO trades at $12.69, down 0.47% on the day, with a bearish technical signal from moving averages and mixed oscillators. The stock faces resistance near $13 and support at $12. Recent news highlights Indonesia's economic initiatives and central bank rate hikes, but the ETF's heavy financials weighting and weak price action persist. Key financial ratios are not provided in the current dataset.
The outlook remains cautious due to technical downtrend and external pressures on Asian equities. Opportunities exist if Indonesia's AI integration and reforestation plans boost economic growth, but risks include currency volatility and limited earnings growth. Investor sentiment is neutral to bearish amid capital outflows from regional markets.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
